JPTRM Vol. 8 No. 1 (May 2020)

Permanent URI for this collection

https://demodspace.chitkara.edu.in/handle/123456789/137

Browse

Browsing JPTRM Vol. 8 No. 1 (May 2020) by Author "Sandeep Arora"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    A Comprehensive Review on Therapeutic Potential of Benzimidazole: A Miracle Scaffold
    (Chitkara University Publications, 2020-05-20) Ritchu Babbar; Swikriti; Sandeep Arora
    Background: Benzimidazole is a category of heterocyclic aromatic compounds formed from the fusion of six membered benzene with five membered imidazolering. The moiety possesses diverse biological and clinical applications. A number of studies have shown that a varied substituent around the benzimidazole nucleus results in pharmacologically active compounds of therapeutic interest. Purpose: Owing to its number of pharmacological properties, this moiety is of choice of interest in designing and synthesis of new therapeutic compounds. The existence of the benzimidazole core in numerous groups of biological agents like antimicrobial, antiviral, antiparasitic, antihypertensive, anticancer, CNS stimulant as well as depressants has made important scaffold for development of many newer therapeutic agents. There is utmost need to understand the synthesis and associated role of benzimidazole derived compounds in different diseases. Therefore, in the present review, we attempt to discuss various derivatives of benzimidazole nucleus with different pharmacological activities. Conclusion: Benzimidazoles have played a great role in discovery of drug and development. Huge attempt has been made towards benzimidazole heterocyclic-based organic compounds with great excellence that resulted in drugs with enormous biological activity. Therapeutic drugs containing benzimidazole nucleus are used in building drugs that serve to be an active area of research. This article becomes a source that will lead to discovery of new opportunities for all researchers interested in benzimidazole-based heterocyclic medicinal chemistry.
  • No Thumbnail Available
    Item
    Phytoalexins: Sources and Their Pharmacological Potential
    (Chitkara University Publications, 2020-05-20) Rakesh K Sindhu; Bhavika Arora; Sandeep Arora
    Background: Plants are easily prone towards microbial infections on exposure to microorganisms and pathogens. In order to defense, plants produce low molecular weight secondary metabolites which were later known as “Phytoalexins”. These molecules have vast therapeutic potential also. Purpose: The purpose of this review is to explore the phytoalexins and their pharmacological effects. Methods: The data included from the articles were published from Web of Science, PubMed, Medline, Scopus, and Embase by using relevant keywords including plants possessing phytoalexins and their specific biological applications. Results: The review insights the potential of phytoalexins in various diseases and to explore phytoalexins applications in human health and disease control. Conclusions: On the basis of this review it may be concluded that phytoalexins have tremendous potential in the treatment and prevention of various life-threatening diseases like diabetes mellitus, cancer, brain damage, and heart attack.
  • No Thumbnail Available
    Item
    Ranitidine Induced Hepatotoxicity: A Review
    (Chitkara University Publications, 2020-05-20) Onkar Bedi; Amit Bandyopadhyay Banerjee; Thakur Gurjeet Singh; Sandeep Arora; Manisha Gupta
    Background: Ranitidine (RAN) is one of the common drugs associated with idiosyncratic adverse drug reactions (IADRs) in humans. It was found to be associated with severe adverse drug reactions due to the presence of contaminants such as N-Nitrosodimethylamine (NDMA) which is claimed to be carcinogenic. As a consequence, on April 1, 2020, United States Food and Drug Administration (USFDA) had decided to call off all the RAN products from the market. The exact cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. Purpose: To summarize and analyze the reason behind the withdrawal of RAN products from the market and whether ranitidine will be available again in future or will FDA withdraw approvals of ranitidine National Drug Authority (NDA) and an abbreviated new drug application (ANDA)? Methods: We performed a systematic PubMed/MEDLINE search of studies investigating the reason behind the withdrawal of RAN products and explored the possible mechanism associated with RAN induced hepatotoxicity. Conclusion: RAN induced liver injury is difficult to diagnose and study because of its relative rarity and unpredictive occurrence. Recent studies suggest that most of the RAN associated idiosyncratic reactions may lead to hepatocyte damage, followed by a series of events, such as activation of specific T- and B-cells, release of proinflammatory mediators like TNFα, interleukins, various cytokines and chemokines. The exact cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. More studies must be carried out on this to know about the exact reason behind RAN associated hepatotoxicity.